{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T16:57:39Z","timestamp":1785257859784,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Prostate cancer (PC) is common cancer worldwide. Several markers have been developed to differentiate between benign prostatic hyperplasia (BPH) from PC. A descriptive retrospective hospital-based study aimed at determining the expression of Cyclin D1 in BPH and PC. The study took place at different histopathology laboratories in Khartoum state, Sudan, from December 2016 to January 2019. Formalin-fixed paraffin-embedded blocks were sectioned and fixed in 3-aminopropyltriethoxysilane coated slides incubated into primary antibody for Cyclin D1. The assessment of immunoreactivity of Cyclin D1 of each section was done using the Gleason scoring system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 153 males\u2019 prostate sections included in this study, of them, 120 (78.4%) were PC, and 33 (21.6%) were BPH. Their age ranged from 45 to 88\u00a0years, mean age was 66.19\u2009\u00b1\u20098.599. 142 (92.8%) did not have a family history of PC, while 11 (7.2%) patients reported having a family history. The Gleason scoring showed a total of 81 (52.9%) patients with high-grade and 39 (25.5%) with low-grade. 118 (97.5%) patients had PC showed positive results for Cyclin D1, while BPH was 3 (2.5%). P value\u2009&lt;\u20090.001. Cyclin D1 staining was associated with high-grade Gleason score and perineural invasion, P value 0.001.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-020-05138-7","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T09:03:53Z","timestamp":1592384633000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunohistochemical expression of Cyclin D1 among Sudanese patients diagnosed with benign and malignant prostatic lesions"],"prefix":"10.1186","volume":"13","author":[{"given":"Eiman Siddig","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna S.","family":"Elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowa","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel E.","family":"Siddig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mintu Elsa","family":"Chacko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman T.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona A.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdalla","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Muneer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6843-3361","authenticated-orcid":false,"given":"Nouh S.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali M. M.","family":"Edris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"issue":"6","key":"5138_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5138_CR2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s12262-010-0180-7","volume":"73","author":"AK Manna","year":"2011","unstructured":"Manna AK, Pathak S, Gayen P, Sarkar DK, Kundu AK. Study of immunohistochemistry in prostatic lesions with special reference to proliferation and invasiveness. Indian J Surg. 2011;73(2):101\u20136.","journal-title":"Indian J Surg"},{"issue":"1","key":"5138_CR3","first-page":"72","volume":"28","author":"Y Xu","year":"2016","unstructured":"Xu Y, Wang Y, Zhou R, Li H, Cheng H, Wang Z, Zhang J. The benign mimickers of prostatic acinar adenocarcinoma. Chin J Cancer Res. 2016;28(1):72.","journal-title":"Chin J Cancer Res"},{"issue":"11","key":"5138_CR4","doi-asserted-by":"publisher","first-page":"e0188068","DOI":"10.1371\/journal.pone.0188068","volume":"12","author":"AB Ortiz","year":"2017","unstructured":"Ortiz AB, Garcia D, Vicente Y, Palka M, Bellas C, Martin P. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma. PLoS ONE. 2017;12(11):e0188068.","journal-title":"PLoS ONE"},{"issue":"4","key":"5138_CR5","doi-asserted-by":"publisher","first-page":"e94508","DOI":"10.1371\/journal.pone.0094508","volume":"9","author":"Y Li","year":"2014","unstructured":"Li Y, Wei J, Xu C, Zhao Z, You T. Prognostic significance of cyclin D1 expression in colorectal cancer: a meta-analysis of observational studies. PLoS ONE. 2014;9(4):e94508.","journal-title":"PLoS ONE"},{"key":"5138_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3349\/ymj.1996.37.2.142","volume":"37","author":"WI Yang","year":"1996","unstructured":"Yang WI, Chung KY, Shin DH, Kim YB. Cyclin D1 protein expression in lung cancer. Yonsei Med J. 1996;37:142\u201350.","journal-title":"Yonsei Med J"},{"issue":"1","key":"5138_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/sj.bjc.6690661","volume":"81","author":"J Keum","year":"1999","unstructured":"Keum J, Kong G, Yang S, Shin D, Park S, Lee J, Lee J. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer. Br J Cancer. 1999;81(1):127.","journal-title":"Br J Cancer"},{"issue":"6","key":"5138_CR8","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1590\/1414-431X20143240","volume":"47","author":"R Pereira","year":"2014","unstructured":"Pereira R, Ravinal R, Costa RS, Lima M, Tucci S, Muglia V, Dos Reis R, Silva GEB. Cyclin D1 expression in prostate carcinoma. Braz J Med Bio Res. 2014;47(6):515\u201321.","journal-title":"Braz J Med Bio Res"},{"issue":"4","key":"5138_CR9","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/cam4.254","volume":"3","author":"IE Saeed","year":"2014","unstructured":"Saeed IE, Weng HY, Mohamed KH, Mohammed SI. Cancer incidence in Khartoum, Sudan: first results from the Cancer Registry, 2009\u20132010. Cancer Med. 2014;3(4):1075\u201384.","journal-title":"Cancer Med"},{"issue":"1","key":"5138_CR10","first-page":"279","volume":"36","author":"ME Saeed","year":"2016","unstructured":"Saeed ME, Cao J, Fadul B, Kadioglu O, Khalid HE, Yassin Z, Mustafa SM, Saeed E, Efferth T. A five-year survey of cancer prevalence in Sudan. Anticancer Res. 2016;36(1):279\u201386.","journal-title":"Anticancer Res"},{"key":"5138_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.canep.2017.01.009","volume":"47","author":"I Kulh\u00e1nov\u00e1","year":"2017","unstructured":"Kulh\u00e1nov\u00e1 I, Bray F, Fadhil I, Al-Zahrani AS, El-Basmy A, Anwar WA, Al-Omari A, Shamseddine A, Znaor A, Soerjomataram I. Profile of cancer in the Eastern Mediterranean region: the need for action. Cancer Epidemiol. 2017;47:125\u201332.","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"5138_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/0046-8177(92)90108-F","volume":"23","author":"DF Gleason","year":"1992","unstructured":"Gleason DF. Histologic grading of prostate cancer: a perspective. Hum Pathol. 1992;23(3):273\u20139.","journal-title":"Hum Pathol"},{"issue":"6","key":"5138_CR13","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/pros.22599","volume":"73","author":"Y Nakamura","year":"2013","unstructured":"Nakamura Y, Felizola SJ, Kurotaki Y, Fujishima F, McNamara KM, Suzuki T, Arai Y, Sasano H. Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ER\u03b2) in human prostate cancer. Prostate. 2013;73(6):590\u20135.","journal-title":"Prostate"},{"issue":"3","key":"5138_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/(SICI)1097-0045(19990215)38:3<175::AID-PROS1>3.0.CO;2-#","volume":"38","author":"S Aaltomaa","year":"1999","unstructured":"Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate. 1999;38(3):175\u201382.","journal-title":"Prostate"},{"issue":"11","key":"5138_CR15","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pros.23833","volume":"79","author":"M Wong","year":"2019","unstructured":"Wong M, Bierman Y, Pettaway C, Kittles R, Mims M, Jones J, Ittmann M. : Comparative analysis of p16 expression among African American and European American prostate cancer patients. Prostate. 2019;79(11):1274\u201383.","journal-title":"Prostate"},{"issue":"10","key":"5138_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1002\/pros.23817","volume":"79","author":"X Wu","year":"2019","unstructured":"Wu X, Scott H, Carlsson SV, Sjoberg DD, Cerundolo L, Lilja H, Prevo R, Rieunier G, Macaulay V, Higgins GS. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate. 2019;79(10):1079\u201389.","journal-title":"Prostate"},{"issue":"9","key":"5138_CR17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1002\/pros.23813","volume":"79","author":"D Duijvesz","year":"2019","unstructured":"Duijvesz D, Rodriguez-Blanco G, Hoogland AM, Verhoef EI, Dekker LJ, Roobol MJ, van Leenders GJ, Luider TM, Jenster G. Differential tissue expression of extracellular vesicle-derived proteins in prostate cancer. Prostate. 2019;79(9):1032\u201342.","journal-title":"Prostate"},{"issue":"7","key":"5138_CR18","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1002\/pros.23787","volume":"79","author":"A Krzyzanowska","year":"2019","unstructured":"Krzyzanowska A, DonDoncow N, Marginean FE, Gaber A, Watson RW, Hellsten R, Bjartell A. Expression of tSTAT3, pSTAT3727, and pSTAT3 705 in the epithelial cells of hormone-na\u00efve prostate cancer. Prostate. 2019;79(7):784\u201397.","journal-title":"Prostate"},{"issue":"8","key":"5138_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/pros.23785","volume":"79","author":"L Nie","year":"2019","unstructured":"Nie L, Pan X, Zhang M, Yin X, Gong J, Chen X, Xu M, Zhou Q, Chen N. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center. Prostate. 2019;79(8):819\u201325.","journal-title":"Prostate"},{"issue":"5","key":"5138_CR20","first-page":"560","volume":"8","author":"LR Zukerberg","year":"1995","unstructured":"Zukerberg LR, Yang W-I, Gadd M, Thor AD, Koerner FC, Schmidt EV, Arnold A. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol. 1995;8(5):560\u20137.","journal-title":"Mod Pathol"},{"issue":"5","key":"5138_CR21","first-page":"1161","volume":"146","author":"H Naitoh","year":"1995","unstructured":"Naitoh H, Shibata J, Kawaguchi A, Kodama M, Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am J Pathol. 1995;146(5):1161.","journal-title":"Am J Pathol"},{"issue":"15","key":"5138_CR22","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/sj.onc.1201719","volume":"16","author":"Y Chen","year":"1998","unstructured":"Chen Y, Martinez LA, LaCava M, Coghlan L, Conti CJ. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1. Oncogene. 1998;16(15):1913.","journal-title":"Oncogene"},{"issue":"2","key":"5138_CR23","first-page":"87","volume":"43","author":"Y Hashimoto","year":"1997","unstructured":"Hashimoto Y, Nakamura N, Kuze T, Abe M, Wakasa H. Intranuclear expression of cyclin D1 protein as a useful prognostic marker for mantle cell lymphoma. Fukushima J Med Sci. 1997;43(2):87\u201398.","journal-title":"Fukushima J Med Sci"},{"issue":"9","key":"5138_CR24","first-page":"1634","volume":"57","author":"S Gansauge","year":"1997","unstructured":"Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N, Beger HG. Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 1997;57(9):1634\u20137.","journal-title":"Cancer Res"},{"issue":"12","key":"5138_CR25","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/bjc.1997.305","volume":"75","author":"K Shin","year":"1997","unstructured":"Shin K, Kong G, Kim W, Lee T, Woo Y, Lee J. Overexpression of cyclin D1 correlates with early recurrence in superficial bladder cancers. Br J Cancer. 1997;75(12):1788.","journal-title":"Br J Cancer"},{"issue":"1","key":"5138_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/(SICI)1097-0045(19990101)38:1<40::AID-PROS5>3.0.CO;2-I","volume":"38","author":"LM Gumbiner","year":"1999","unstructured":"Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, Pretlow TG, Tricoli JV. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate. 1999;38(1):40\u20135.","journal-title":"Prostate"},{"issue":"1","key":"5138_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1471-230X-4-22","volume":"4","author":"AA Bahnassy","year":"2004","unstructured":"Bahnassy AA, Zekri A-RN, El-Houssini S, El-Shehaby AM, Mahmoud MR, Abdallah S, El-Serafi M. Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients. BMC Gastroenterol. 2004;4(1):22.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"5138_CR28","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1046\/j.1464-410x.2000.00916.x","volume":"86","author":"W Dunsmuir","year":"2000","unstructured":"Dunsmuir W, Gillett C, Meyer L, Young M, Corbishley C, Eeles R, Kirby R. Molecular markers for predicting prostate cancer stage and survival. BJU Int. 2000;86(7):869\u201378.","journal-title":"BJU Int"},{"issue":"30","key":"5138_CR29","first-page":"15","volume":"30","author":"E Ozbek","year":"2000","unstructured":"Ozbek E, Mizrak B, Ozbek M, Buyukberber S, Davarci M. Cyclin-D1 protooncogen expression in prostate cancer. Turk J Cancer. 2000;30(30):15\u201321.","journal-title":"Turk J Cancer"},{"issue":"4","key":"5138_CR30","first-page":"753","volume":"80","author":"BV Kallakury","year":"1997","unstructured":"Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP, Ross JS. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Interdiscip Int J Am Cancer Soc. 1997;80(4):753\u201363.","journal-title":"Interdiscip Int J Am Cancer Soc"},{"issue":"2","key":"5138_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/(SICI)1097-0045(19980501)35:2<95::AID-PROS2>3.0.CO;2-F","volume":"35","author":"EKH Han","year":"1998","unstructured":"Han EKH, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate. 1998;35(2):95\u2013101.","journal-title":"Prostate"},{"issue":"24","key":"5138_CR32","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1158\/1078-0432.CCR-15-0744","volume":"21","author":"H Tsai","year":"2015","unstructured":"Tsai H, Morais CL, Alshalalfa M, Tan H-L, Haddad Z, Hicks J, Gupta N, Epstein JI, Netto GJ, Isaacs WB. Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res. 2015;21(24):5619\u201329.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5138_CR33","first-page":"1891","volume":"6","author":"M Drobnjak","year":"2000","unstructured":"Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res. 2000;6(5):1891\u20135.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5138_CR34","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1365-2559.2011.03800.x","volume":"58","author":"A Fleischmann","year":"2011","unstructured":"Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology. 2011;58(5):781\u20139.","journal-title":"Histopathology"},{"issue":"17","key":"5138_CR35","doi-asserted-by":"publisher","first-page":"8188","DOI":"10.1158\/0008-5472.CAN-07-0418","volume":"67","author":"Y He","year":"2007","unstructured":"He Y, Franco OE, Jiang M, Williams K, Love HD, Coleman IM, Nelson PS, Hayward SW. Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res. 2007;67(17):8188\u201397.","journal-title":"Cancer Res"},{"issue":"3","key":"5138_CR36","first-page":"219","volume":"54","author":"G Ding","year":"2012","unstructured":"Ding G, Liu J, Feng C, Jiang H, Xu J, Ding Q. Slug regulates Cyclin D1 expression by ubiquitin-proteasome pathway in prostate cancer cells. Panminerva Med. 2012;54(3):219\u201323.","journal-title":"Panminerva Med"},{"issue":"1","key":"5138_CR37","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ijrobp.2010.11.023","volume":"82","author":"BF Koontz","year":"2012","unstructured":"Koontz BF, Tsivian M, Mouraviev V, Sun L, Vujaskovic Z, Moul J, Lee WR. Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. Int J Radiation Oncol Biol Phys. 2012;82(1):200\u20133.","journal-title":"Int J Radiation Oncol Biol Phys"},{"issue":"5","key":"5138_CR38","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1464-410X.2012.11114.x","volume":"111","author":"G Lughezzani","year":"2013","unstructured":"Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU Int. 2013;111(5):723\u201330.","journal-title":"BJU Int"},{"issue":"Suppl 6","key":"5138_CR39","first-page":"S3","volume":"5","author":"TJ Wilt","year":"2003","unstructured":"Wilt TJ, Abrahamsson P-A, Crawford ED, Lucia MS, Sakr WA, Schalken J. Prostate cancer: epidemiology and screening. Rev Urol. 2003;5(Suppl 6):S3.","journal-title":"Rev Urol"},{"issue":"2","key":"5138_CR40","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0022-5347(01)65201-7","volume":"157","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol. 1997;157(2):559\u201362.","journal-title":"J Urol"},{"issue":"4","key":"5138_CR41","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4103\/0973-1482.92021","volume":"7","author":"JN Kulkarni","year":"2011","unstructured":"Kulkarni JN, Valsangkar RS, Jadhav YR, Singh DP. Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (\u2264\u20096). J Cancer Res Therap. 2011;7(4):459.","journal-title":"J Cancer Res Therap"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05138-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-020-05138-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05138-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T19:25:31Z","timestamp":1623871531000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-05138-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5138"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-05138-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.11132\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.11132\/v2","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"3 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Faculty of Medical Laboratory Sciences Research Ethics Committee\u2014University of Khartoum, Sudan. Informed consent was obtained from each participant prior to enrollment using writing and verbal informed consent in case of illiterate patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare that they have no competing interest<i>s.<\/i>","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}